Cosmosiin Induces Apoptosis in Colorectal Cancer by Inhibiting PD-L1 Expression and Inducing ROS.
Jung Ho HanEun-Ji LeeWonyoung ParkJang-Gi ChoiKi-Tae HaHwan-Suck ChungPublished in: Antioxidants (Basel, Switzerland) (2023)
Immunotherapies, particularly those concerning immune checkpoint inhibitors, have transformed cancer treatment in recent years. Programmed death-ligand 1 (PD-L1) is a key target for immunotherapy that is overexpressed in the cells of colorectal cancer, a widespread malignant cancer that poses a significant healthcare challenge. This study investigated the effects of cosmosiin treatment on colorectal cancer cell lines. Cosmosiin is a naturally occurring flavone glycoside compound that has potential health benefits, including antioxidant and immunomodulatory effects. This study showed that cosmosiin effectively suppresses the expression of PD-L1 and triggers apoptosis, which is facilitated through pathways that are related to reactive oxygen species. These outcomes suggest that cosmosiin could be a promising candidate for an immune checkpoint inhibitor in the treatment of colorectal cancer.
Keyphrases
- healthcare
- reactive oxygen species
- oxidative stress
- cell cycle arrest
- signaling pathway
- induced apoptosis
- public health
- cell death
- mental health
- squamous cell carcinoma
- dna damage
- type diabetes
- endoplasmic reticulum stress
- papillary thyroid
- young adults
- cell proliferation
- combination therapy
- skeletal muscle
- lymph node metastasis
- insulin resistance
- health promotion
- weight loss